Evotec Presents Growth Drivers of ‘Autobahn to Cures’ at Capital Markets Day

CO-OWNED PIPELINE: EVOLUTION FROM DISCOVERY INTO CLINICAL-STAGE PROJECTS
PRECISION MEDICINE DEVELOPING MEDICINES OF THE FUTURE WITH NOVEL AI & ML PREDICTION TOOLS
MULTIMODALITY PLATFORMS DRIVING R&D PROJECTS TOWARDS HIGHER EFFICIENCY AND BROADER ACCESS AT HIGH SPEED

HAMBURG, GERMANY / ACCESSWIRE / November 19, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today presents the progress made in accelerating its co-owned pipeline and its global infrastructure "The R&D Autobahn to Cures". The Company is hosting a virtual Capital Markets Day for investors and interested stakeholders.

Evotec pursues a unique strategy to become the globally leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a very large co-owned pipeline.

The Company will provide a detailed business overview focusing on

building long-term value on its co-owned pipeline
highly efficient and effective platforms as future tools for data generation and analysis (e.g. PanOmics and PanHunter)
iPSC as a leading new paradigm for early disease relevance and data-driven precision medicine
operational excellence, from the industry-leading "R&D Autobahn to Cures" over artificial intelligence and machine learning tools and applications to the facility of the future in Biologics

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "I am pleased to present together with my Team selected highlights of the scientific potential of all our platforms. Precision medicine and better access to more affordable drugs will define the road into the future of this industry. Evotec will be an essential part of the infrastructure for all relevant technologies and modalities."

About the virtual Capital Markets Day
Evotec will host its virtual Capital Markets Day on 19 November 2020, starting at 8.30 am EST (2.30 pm CET, 1.30 pm GMT). The meeting will take place via a live webcast and a replay of the recorded webcast will be available on www.evotec.com.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG via EQS Newswire

ReleaseID: 617551